Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.32 |
| ▸ | GABRR1 | P24046 | 2/20 | 0.31 |
| ▸ | GABRR2 | P28476 | 2/20 | 0.31 |
| ▸ | BLM | P54132 | 2/20 | 0.31 |
| ▸ | GABRR3 | A8MPY1 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | APEX1 | P27695 | 1/20 | 0.31 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15516197 | 1.00 | HCAR2 (0.32) | HCAR2GABRR1GABRR2BLMGABRR3 | |
| SCHEMBL5633056 | 0.83 | CTSK (0.33) | — | |
| SCHEMBL13619240 | 0.82 | — | — | |
| SCHEMBL15508217 | 0.81 | MAPT (0.40) | HCAR2NPSR1 | |
| SCHEMBL7749013 | 0.80 | — | — | |
| SCHEMBL17787236 | 0.78 | CTSK (0.31) | — | |
| SCHEMBL5632680 | 0.78 | CTSK (0.31) | — | |
| SCHEMBL14418880 | 0.78 | CTSK (0.31) | — | |
| SCHEMBL9595469 | 0.78 | ALDH1A1 (0.31) | HCAR2LMNATDP1 | |
| SCHEMBL9595479 | 0.78 | ALDH1A1 (0.31) | HCAR2LMNATDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9809566-B2 | Organocatalytic process for asymmetric synthesis of decanolides | COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH (IN) | 2017-11-07 | — | — | US | disclosed |
| US-9765048-B2 | Organocatalytic process for asymmetric synthesis of decanolides | COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH (IN) | 2017-09-19 | — | — | US | disclosed |
| US-20160272608-A1 | ORGANOCATALYTIC PROCESS FOR ASYMMETRIC SYNTHESIS OF DECANOLIDES | COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH (IN) | 2016-09-22 | — | — | US | disclosed |
| US-20160272609-A1 | ORGANOCATALYTIC PROCESS FOR ASYMMETRIC SYNTHESIS OF DECANOLIDES | COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH (IN) | 2016-09-22 | — | — | US | disclosed |
| US-9353077-B2 | Organocatalytic process for asymmetric synthesis of decanolides | COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH (IN) | 2016-05-31 | — | — | US | disclosed |
| US-20150210665-A1 | ORGANOCATALYTIC PROCESS FOR ASYMMETRIC SYNTHESIS OF DECANOLIDES | COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH (IN) | 2015-07-30 | — | — | US | disclosed |
| WO-2014037964-A2 | ORGANOCATALYTIC PROCESS FOR ASYMMETRIC SYNTHESIS OF DECANOLIDES | COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH (IN) | 2014-03-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160272609-A1 | ORGANOCATALYTIC PROCESS FOR ASYMMETRIC SYNTHESIS OF DECANOLIDES | CDC14A, CDC14B, DDOST | HCAR2 4083/4885GABRR1 3333/4885GABRR2 2315/4885 |
| US-20150210665-A1 | ORGANOCATALYTIC PROCESS FOR ASYMMETRIC SYNTHESIS OF DECANOLIDES | CDC14A, CDC14B, DDOST | HCAR2 4083/4885GABRR1 3333/4885GABRR2 2315/4885 |
| US-20160272608-A1 | ORGANOCATALYTIC PROCESS FOR ASYMMETRIC SYNTHESIS OF DECANOLIDES | CDC14A, CDC14B, DDOST | HCAR2 4083/4885GABRR1 3333/4885GABRR2 2315/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.